Drug Trial Radar · NCT00989027
Impact of Uterotonic Agents on Isolated Human Myometrium
Last checked: Nov 20, 2026Latest source record: Feb 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jun 2007
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 2, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the ability of a sample of uterine muscle tissue to contract in the presence of various drugs. The drugs studied are typically used to contract the uterus when a pregnant patient continues to bleed after delivery. Amongst the uterotonic drugs (used to contract the uterus), namely oxytocin, ergonovine and carboprost, the most effective one to use is not known. The investigators will be testing uterine muscle samples in the presence of these drugs at various concentrations, to see what their contractility measures over time, as compared with a control sample, in which no drugs will be applied.
Conditions
- Postpartum Hemorrhage
Interventions
OxytocinDrug
Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
ErgonovineDrug
Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
CarboprostDrug
Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Oxytocin and ErgonovineDrug
Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Oxytocin and CarboprostDrug
Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amplitude of contractionTime frame: 6-8 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mount Sinai Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.